Extended Review Timeline for Certain Applications under Proposed PDUFA V

May 21, 2012

The Prescription Drug User Fee Act (PDUFA) is due to be reauthorized by the end of September this year. Along with the usual increases in fees, the latest version of the act (PDUFA V) includes some new initiatives. One of these is a program for enhanced review transparency and communication which will apply to all New Molecular Entity (NME) New Drug Applications (NDAs) and original Biologics License Applications (BLAs). This includes applications that are submitted following a Refuse-To-File action.

Included in the program are specific meetings between the Agency and the Sponsor (e.g. pre-submission meeting, late-cycle meeting) as well as other communications. One very important change to this program affects the overall review timeline for a submission. For NME NDA and original BLA submissions that are filed by FDA under the program, the PDUFA review clock will begin at the conclusion of the 60 calendar day filing review period that begins on the date of FDA receipt of the original submission. What this means is that sponsors who submit NME NDAs and original BLAs on or after October 1, 2012 will have a two month longer review period than those submitted prior to that date. For sponsors looking at a filing date near the September 30th deadline, this new program provides additional incentive to file before the new timeline takes effect.

If you have any questions or thoughts on this blog post or others, please contact us.

TAGS:

February 7, 2013

Generic Drug User Fee Act (GDUFA) Overview

FDA user fees have been a fact of life for regulated industries for nearly two decades. As you continue to comply by paying the fees, you should understand what the revenue does for you....

April 13, 2016

FDA Works to Reduce Medical Errors, Part One: Background & Overview of FDA’s Proprietary Naming Guidance

In September 2007, the Prescription Drug User Fee Act (PDUFA IV) was reauthorized and expanded, broadening and strengthening FDA’s drug safety program. As part of PDUFA’s reauthorization, the Agency...

August 12, 2022

FDA Solicits Feedback on ANDA Submissions – Amendments to ANDAs Under GDUFA Guidance, Appendix A

Ahead of this year’s reauthorization of the Generic Drug User Fee Amendments (GDUFA) , FDA has established a docket to solicit comments on the content of Appendix A in the July 2018 guidance for...